Department of Bioengineering, University of California Los Angeles, Los Angeles, CA, USA.
Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York, NY, USA.
Acta Neuropathol Commun. 2024 Oct 3;12(1):157. doi: 10.1186/s40478-024-01868-y.
While Alzheimer's disease and other neurodegenerative diseases have traditionally been viewed as brain disorders, there is growing evidence indicating their manifestation in the eyes as well. The retina, being a developmental extension of the brain, represents the only part of the central nervous system that can be noninvasively imaged at a high spatial resolution. The discovery of the specific pathological hallmarks of Alzheimer's disease in the retina of patients holds great promise for disease diagnosis and monitoring, particularly in the early stages where disease progression can potentially be slowed. Among various retinal imaging methods, hyperspectral imaging has garnered significant attention in this field. It offers a label-free approach to detect disease biomarkers, making it especially valuable for large-scale population screening efforts. In this review, we discuss recent advances in the field and outline the current bottlenecks and enabling technologies that could propel this field toward clinical translation.
虽然阿尔茨海默病和其他神经退行性疾病传统上被视为脑部疾病,但越来越多的证据表明它们也会在眼睛中表现出来。视网膜是大脑的发育延伸,是唯一可以高空间分辨率进行非侵入性成像的中枢神经系统部分。在患者的视网膜中发现阿尔茨海默病的特定病理特征,为疾病诊断和监测带来了巨大的希望,特别是在疾病进展可能被减缓的早期阶段。在各种视网膜成像方法中,高光谱成像在该领域引起了广泛关注。它提供了一种无标记的方法来检测疾病生物标志物,使其特别适合大规模人群筛查工作。在这篇综述中,我们讨论了该领域的最新进展,并概述了当前的瓶颈和使能技术,这些技术可能会推动该领域向临床转化。